1. Pink Sheet
  2. >>Legislation

Opioid Legislation Would Require US FDA Guidance On Non-Opioid Pain Medication Development

 
• By Michael Cipriano

Senate HELP Committee unanimously advances bill that would also boost FDA's power over unit dose packaging and improve inspection of international mail facilities. 

People running from dangerous pills

The US Senate Committee on Health, Education, Labor and Pensions unanimously voted to advance an opioid package that would require the US FDA to clarify the development and regulatory pathways for non-addictive and non-opioid pain medications by a 23-0 margin.

The Opioid Crisis Response Act of 2018 (S.2680) got the nod from the HELP Committee at an April 24 markup...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.